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Abstract
Background: In vivo studies on HIV-1 pathogenesis and testing of antiviral strategies have been hampered by the lack of
an immunocompetent small animal model that is highly susceptible to HIV-1 infection. Since native rodents are non-
permissive, we developed transgenic rats that selectively express the HIV-1 receptor complex, hCD4 and hCCR5, on
relevant target cells. These animals display a transient low-level plasma viremia after HIV-1YU-2 infection, demonstrating
HIV-1 susceptibility in vivo. However, unlike macrophages, primary CD4 T-cells from double-transgenic animals fail to
support viral spread ex vivo. To identify quantitative limitations or absolute blocks in this rodent species, we quantitatively
assessed the efficiency of key steps in the early phase of the viral replication cycle in a side-by-side comparison in infected
cell lines and primary T-cells from hCD4/hCCR5-transgenic rats and human donors.
Results: Levels of virus entry, HIV-1 cDNA synthesis, nuclear import, and integration into the host genome were shown
to be remarkably similar in cell lines and, where technically accessible, in primary T-cells from both species. In contrast,
a profound impairment at the level of early HIV gene expression was disclosed at the single-cell level in primary rat T-
cells and most other rat-derived cells. Macrophages were a notable exception, possibly reflecting the unique
transcriptional milieu in this evolutionarily conserved target cell of all lentiviruses. Importantly, transient trans-
complementation by ex vivo nucleofection with the Tat-interacting protein Cyclin T1 of human origin markedly elevated
HIV gene expression in primary rat T-cells.
Conclusion: This is the first study that has quantitatively determined the efficiency of consecutive steps in the HIV-1
replication cycle in infected primary HIV target cells from a candidate transgenic small animal and compared it to human
cells. Unlike cells derived from mice or rabbits, rat cells complete all of the early steps in the HIV-1 replication cycle,
including provirus integration in vivo, with high efficiency. A deficiency in gene expression was disclosed at the single cell
level and could be counteracted by the human pTEFb transcription complex factor Cyclin T1. Collectively, these results
provide the basis for the advancement of this transgenic rat model through strategies aimed at boosting HIV-1 gene
expression in primary rat CD4 T-cells, including human Cyclin T1 transgenesis.
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Background
A highly HIV-permissive rodent with an intact and well-
defined immune system would be a boon for the study of
HIV pathogenesis and the rapid preclinical evaluation of
antiviral strategies. However, native mice and rats cannot
be infected by HIV. Species-specific barriers restricting
HIV-1 replication in rodents manifest themselves at vari-
ous steps of the viral replication cycle. Over the past dec-
ade, much has been learned about the complex interplay
of virus and host, and this work has resulted in a greater
molecular understanding of these restrictions in cell lines
derived from candidate species, including mice, rats, rab-
bits, and hamsters. The first important advance was an
appreciation of human chemokine receptors, most nota-
bly human CCR5 (hCCR5) and CXCR4 (hCXCR4), as
cofactors with human CD4 (hCD4) for efficient binding,
fusion, and entry of HIV-1 (reviewed in [1]). Indeed, co-
expression of hCD4 and hCCR5 or hCXCR4 in cell lines
from several small animals [2-9] or in transgenic mice and
rats [10-12] is necessary and sufficient for HIV-1 entry,
albeit at efficiencies which were suggested to be low [7,9].
More recently, early HIV-1 post-entry barriers have been
described in an adherent rabbit cell line [13] and cultured
mouse T-cells [5,14], the molecular basis of which has not
been defined. Also, efficient Tat-dependent viral gene
expression from the HIV-1 long terminal repeat (LTR)
occurred in cell lines from mice and hamsters only in the
presence of Cyclin T1 of human origin [15]. Orthologues
from mouse and hamster, in association with cyclin-
dependent kinase CDK9, cannot bind the TAR stem-loop
near the 5'-end of nascent HIV-1 transcripts. Efficient HIV-
1 transcript elongation by the cellular RNA polymerase II
depends on this critical process [16,17]. Interestingly in
this context, previous reports suggested considerably
higher levels of HIV gene expression in infected, rat-
derived Rat2 cells compared to mouse NIH-3T3 and ham-
ster CHO cells, even in the absence of human Cyclin T1
expression [4,7,9].
Additional downstream barriers in rodent cells may limit
the production of infectious virus [18]. Specifically, the
function of HIV-1 Rev in regulating the splicing and
nuclear export of viral transcripts [7,9,19] seems
impaired. Moreover, a recessive defect at the level of HIV-
1 assembly [7,20] and a maturation or APOBEC3G-
dependent infectivity defect [9,21] have been proposed in
certain mouse and hamster cell lines, although their sever-
ity is still controversial [4,7,9,11].
In contrast, certain rat cell lines co-expressing hCD4 and
hCCR5 supported a full HIV-1 replication cycle and the
release of infectious virions, although virus production in
a single replication cycle was still less than 10% of that in
human reference cultures [4]. Thus, the major block to
HIV-1 infection in rat cells appeared to be at the level of
cellular entry and could be overcome by expression of the
HIV-1 receptor complex. Based on these findings, immu-
nocompetent Sprague-Dawley rats were generated that
transgenically express hCD4 and hCCR5 selectively on
CD4 T-cells, macrophages, and microglia [11]. After sys-
temic challenge with the R5 HIV-1 strain YU-2 (HIV-1YU-
2), these double-transgenic rats harbored significant levels
of episomal HIV-1 cDNA species in lymphatic organs and
displayed a low-level plasma viremia up to 7 weeks post-
challenge, demonstrating susceptibility to HIV-1 in vivo
[11]. Furthermore, a recent proof-of-principle study high-
lighted the utility of these double-transgenic rats for a
rapid preclinical evaluation of the inhibitory potency and
of the pharmacokinetic properties of antiviral compounds
targeting HIV entry or reverse transcription [22].
Although promising, the model still has limitations: levels
of plasma viremia were modest and not sustained. This
may be due to a cell type-specific block to productive HIV-
1 infection in double-transgenic rats. Primary rat macro-
phages and microglia, but not cultures from T-lym-
phocytes, could be productively infected by recombinant
and primary R5 HIV-1 strains [11]. This barrier to HIV-1
replication in primary rat CD4 T-cells apparently pre-
vented this important cell population from contributing
to the viral load in vivo and further manipulations of this
rodent model may be required to achieve high-level per-
missivity.
To gain insight into the nature and magnitude of the lim-
itation, the current study focused on a quantitative side-
by-side assessment of early steps in the HIV-1 replication
cycle in infected primary T-cells from hCD4/hCCR5-trans-
genic rats and humans. In principle, the exclusive analysis
of one HIV cDNA species or gene product would solely
reflect a "cumulative" efficiency of all preceding steps and
may completely mask severe quantitative deviations, be it
higher or lower, in the efficiency of individual steps in the
rat-human species comparison. For example, a 10-fold
enhancement at the level of HIV entry in hCD4/hCCR5-
transgenic rat T-cells could potentially compensate a 10-
fold reduction at the level of reverse transcription, result-
ing in comparable levels of preintegration complexes for
subsequent nuclear import and integration. Knowledge
on the efficiency of individual steps in the HIV life cycle is
thus pertinent for the validation of this HIV-susceptible
small animal model and provides the basis for the inter-
pretation and predictive value of in vivo infection studies.
Consequently, the efficiencies of virion fusion, reverse
transcription and nuclear import, provirus formation, and
early viral gene expression were analyzed to pinpoint
quantitative limitations or absolute blocks in the early
phase of replication.Retrovirology 2007, 4:53 http://www.retrovirology.com/content/4/1/53
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Results
Primary T-cells from hCD4/hCCR5-transgenic rats support 
a productive infection by MoMLV, but not by HIV-1, in ex 
vivo cultures
We first investigated the ability of HIV-1 to productively
infect and spread in primary rat T-cells that transgenically
express the HIV-1 receptor complex. Spleen-derived T-
cells from a hCD4/hCCR5-transgenic or from a hCD4-
transgenic control rat, or T-cells derived from human
peripheral blood were infected with HIV-1YU-2, and the
infection kinetics were followed by monitoring p24 CA
concentrations in culture supernatants. As expected, acti-
vated human T-cells showed a productive and AZT-sensi-
tive infection (Fig. 1A). In contrast, supernatants from
HIV-1YU-2-exposed rat T-cell cultures contained only back-
ground levels of p24 CA that did not increase over time
(Fig. 1A).
To exclude the presence of a broad-spectrum anti-retrovi-
ral activity in these rat T-cell cultures, we challenged them
in parallel with a replication-competent ecotropic Molo-
ney murine leukemia virus carrying an IRES-egfp element
in the untranslated region between env and the 3'-LTR
(MoMLV-GFP). Rat T-cell cultures were highly susceptible
to MoMLV-GFP infection, reflected by rapidly increasing
percentages of GFP-positive T-cells (Fig. 1B). Conversely,
human T-cells did not support a MoMLV-GFP infection,
due to the absence of murine cationic amino acid trans-
porter-1, the rodent-specific entry receptor for ecotropic
MoMLV [23].
Thus, primary rat T-cells, despite expression of the HIV-1
receptor complex, fail to support a productive and spread-
ing HIV-1 infection, but are highly permissive for infec-
tion by a mammalian gamma-retrovirus and thus do not
impose a general restriction to retroviral infection.
HIV-1 efficiently enters primary T-cells from hCD4/
hCCR5-transgenic rats
We quantitatively analyzed each early step in the HIV-1
replication cycle with human T-cells serving as a reference.
First, the efficiency of HIV-1 entry was assessed in a flow
cytometry-based virion-fusion assay [24,25]. T-cells from
both species, activated for 5–10 days, were challenged
with HIV-1YU-2 virions carrying BlaM-Vpr. The cell-perme-
able CCF2 substrate was introduced into the target cells.
After virion fusion, BlaM-Vpr cleaves CCF2, and the
altered fluorescence emission serves as a sensitive and spe-
cific marker for viral entry. Notably, cell-surface levels of
hCD4 were similar, but levels of hCCR5 were markedly
higher on CD4 T-cells from transgenic rats than on those
from their human counterparts ([11] and data not
shown).
The percentages of T-cells from hCD4/hCCR5-transgenic
rats and humans that allowed HIV-1YU-2 entry was statisti-
cally indistinguishable (1.2 ± 1.0% and 1.4 ± 1.3%,
respectively; p = 0.66; n.s.; Mann-Whitney U test) (Fig. 2A
and 2B). Mock-infected T-cells or T-cells that had been
treated either with the fusion inhibitor enfuvirtide (T20)
or with the CCR5 antagonist TAK-779 before exposure to
the cell-free viral inoculum (50 ng p24 CA) displayed only
background levels of cleaved CCF2-positive cells (Fig. 2A
and 2B). As an additional control of specificity, the
CXCR4 antagonist AMD3100 did not significantly (p =
0.9 (human); p = 0.2 (rat)) affect the ability of the R5 HIV-
1 strain to fuse with these primary T-cells.
To explore species-specific differences in the relationship
between the dose of inoculum and the efficiency of virion
fusion, primary T-cells were exposed to increasing doses
of HIV-1R7/3YU-2 Env GFP carrying BlaM-Vpr (Fig. 2C, the
presence of the GFP gene is unimportant in this assay). In
a titration of the inoculum covering three orders of mag-
nitude, T-cells from hCD4/hCCR5-transgenic rats sup-
ported HIV-1 entry at levels that closely matched those of
their human counterparts (Fig. 2C). Human T-cells, which
had been pretreated with an anti-CCR5 antibody, and T-
cells from a hCD4-transgenic rat served as controls and
were largely refractory to virion fusion. In summary, these
results show that expression of the HIV-1 receptor com-
plex on primary rat T-cells efficiently overcomes the HIV-
HIV-1, in contrast to MoMLV, does not spread in primary T- cells from hCD4/hCCR5-transgenic rats Figure 1
HIV-1, in contrast to MoMLV, does not spread in pri-
mary T-cells from hCD4/hCCR5-transgenic rats. (A) 
Activated primary T-lymphocytes from a human donor, a 
hCD4/hCCR5-transgenic, or a hCD4-single-transgenic rat 
were infected with HIV-1YU-2 (5 ng p24 CA per 2–3 × 106 
cells) overnight and washed. Culture supernatants were 
monitored for the presence of p24 CA. Where indicated, 
cultures were treated with AZT (10 μM). (B) The same cul-
tures were exposed to replication-competent ecotropic 
MoMLV-GFP. Percentages of GFP-positive, productively 
infected cells were determined by flow cytometry. All values 
are the arithmetic mean ± S.D. of triplicates. Data are repre-
sentative for two independent experiments.
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Transgenic expression of hCD4 and hCCR5 efficiently overcomes the HIV-1 entry block in primary rat T-lymphocytes Figure 2
Transgenic expression of hCD4 and hCCR5 efficiently overcomes the HIV-1 entry block in primary rat T-lym-
phocytes. Fusion of HIV-1YU-2 virions carrying BlaM-Vpr was analyzed in primary T-cells from humans or hCD4/hCCR5-trans-
genic rats by multi-parameter flow cytometry [22,25]. (A) Representative FACS dot plots for the detection of cleaved CCF2 
substrate, reflecting HIV-1 entry. T-cells from humans (upper panels) and double-transgenic rats (lower panels) were either 
mock-infected (left panels) or infected with HIV-1YU-2 (50 ng HIV-1 p24 CA per 2–3 × 106 cells), either without (middle panels) 
or with (right panels) the fusion inhibitor T20 (50 μM). (B) Results from virion-fusion assays with T-cells from 5–9 different 
donors per species. Were indicated, the CCR5 antagonist TAK-779, the CXCR4 antagonist AMD3100 (both 1 μM), or T20 
(50 μM) were added 15–30 min before virus challenge. Symbols indicate arithmetic means of triplicates from one virion-fusion 
experiment; horizontal bars depict the arithmetic mean ± S.E.M. of all experiments (n.s. = not significant; p = 0.66; * p ≤ 0.02) 
(C) Titration of HIV-1R7/3YU-2 Env GFP carrying BlaM-Vpr in virion-fusion assays on primary T-cells from both species. Where 
indicated (filled triangle) the anti-hCCR5 mAb 2D7 (50 μg/ml) were added to cells 15–30 min before virus challenge.
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1 entry block. This suggests that limitations further down-
stream in the replication cycle restrict productive infection
in these rodent cells.
Nuclear import of de novo synthesized viral DNA genomes 
is similar in primary T-cells from rats and humans
Next, we determined if the HIV-1 replication defect in pri-
mary rat T-cells could be accounted for by a reduced effi-
ciency of reverse transcription or nuclear import of newly
synthesized HIV-1 cDNA, as suggested for mouse T-cells
[5,14]. To ensure comparable conditions in the cross-spe-
cies comparisons, infections were genetically limited to a
single round. As a consequence, the absolute levels of
individual processes in this primary cell type were gener-
ally low. Infections were conducted with HIV-1 generated
from a replication-deficient HIV-1NL4-3E- GFP backbone
pseudotyped with YU-2 Env. This approach allowed a
kinetic analysis of the formation of HIV-1 2-LTR circles. 2-
LTR circles are an episomal HIV cDNA species, are formed
exclusively in the nucleus by cellular ligases of the non-
homologous DNA end joining pathway [26], and serve as
a quantitative marker for reverse transcription and nuclear
import of the viral cDNA genome [27].
2-LTR circles were detected in infected primary T-cells
from both species, and peak levels differed by no more
than twofold (Fig. 3). In contrast, no 2-LTR circles could
be detected in efavirenz-treated cultures or cultures from a
hCD4-single-transgenic rat, demonstrating that the
amplified episomal HIV-1 cDNAs had been generated de
novo  after a receptor-complex-mediated infection and
were not present in the inoculum. Furthermore, flow cyto-
metric analysis 96 h after infection showed similar per-
centages of T-cells expressing GFP from the nef locus (0.7–
0.9% GFP-positive cells, Fig. 3) for infected cultures from
both species, and DNA extracts from samples taken at the
same time point contained comparable levels of 2-LTR cir-
cles (0.53–0.81 copies per ng of DNA; Fig. 3). Thus,
infected primary rat T-cells appear to support reverse tran-
scription and nuclear import of de novo synthesized HIV-
1 cDNA at levels similar to human reference cells, and
early HIV gene products can be expressed. These results
suggest that limitations underlying the replication block
in infected T-cells from this rodent species must be acting
at a step after nuclear entry of the preintegration complex.
A quantitative nested PCR to detect integrated HIV-1 DNA 
in rat cells
To assess the next major step in the HIV-1 replication
cycle, we quantified provirus formation in infected rat
cells. In principle, a defect at the level of integration can
completely abrogate HIV-1 replication, but may still allow
expression of early viral proteins, including Nef, from epi-
somes in the first round of infection [28,29].
Similar to a reported nested PCR strategy to specifically
amplify HIV-1 integrated in proximity to genomic Alu
repeat elements in human cells [30], we designed a nested
real-time PCR assay to detect integrated HIV-1 provirus in
rat cells by employing an ID consensus sequence within
the rat BC1 RNA gene [31,32] as the rodent repeat target
for the cellular anchor primer pair. To serve as standards
for species-specific quantitative analyses of provirus for-
mation, stable populations of human and rat cell lines
containing integrated HIV-1 proviruses were generated
(Fig. 4A): adherent HeLa (human) and Rat2 (rat) cells
were infected with VSV-G pseudotyped HIV-1NL4-3E- GFP
at a low multiplicity of infection and subsequently pas-
saged for 7 weeks to allow complete loss of unintegrated
HIV-1 cDNA species. After an overnight-stimulation with
the histone deacetylase inhibitor trichostatin A, GFP-
expressing cells were enriched by flow cytometric sorting,
and bulk cultures of these provirus-containing, heteroge-
neous cell populations, named HeLaint and Rat2int, were
expanded. Since these cells no longer contain uninte-
grated HIV-1 cDNA species, the absolute number of inte-
grated proviruses per ng cellular DNA in HeLaint and
Reverse transcription and nuclear import of de novo synthe- sized HIV-1 cDNA are well supported in T-cells from hCD4/ hCCR5-transgenic rats Figure 3
Reverse transcription and nuclear import of de novo 
synthesized HIV-1 cDNA are well supported in T-
cells from hCD4/hCCR5-transgenic rats. Primary T-
cells from a human donor or from transgenic rats were 
exposed to YU-2 Env pseudotyped HIV-1NL4-3E- GFP. At the 
indicated time points, post-infection samples were taken 
from cultures, and the relative levels of 2-LTR circles in cell 
extracts were scored by quantitative PCR. The percentage of 
GFP-positive cells at day 4 after infection is given in parenthe-
ses.
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Establishment and validation of a real-time PCR for HIV-1 integrants in rat cells Figure 4
Establishment and validation of a real-time PCR for HIV-1 integrants in rat cells. (A) Schematic of the generation of 
Rat2int (rat) and HeLaint (human) cells, carrying HIV-1NL4-3E- GFP, as species-specific HIV-1 integration standards. (B) PCR strat-
egy of the nested rat integration PCR. In the first round of PCR, a segment of integrated HIV-1 cDNA was amplified by one 
primer annealing in the HIV-1 LTR (primer #1521) and two outward-facing primers targeting the rat ID element (primers 
#1734 and #1782). To increase specificity, LTR primer #1521 contains a lambda-phage heel sequence at the 5'-end [30]. In a 
nested, second-round PCR, a lambda-specific primer (primer #1522), a second LTR primer (primer #1523), as well as an HIV-
1 LTR-specific probe (probe #1524) were employed to exclusively amplify products generated during the first-round PCR. (C) 
Technical validation of species-specific integration PCR on Rat2int or HeLaint [30] cells. Levels of HIV-1 integrants from the 
complete standard PCR reaction were arbitrarily set to 100%, and levels determined for several specificity controls (omission 
(w/o) of LTR primer #1521, omission (w/o) of cellular anchor primer pair (BC, #1734 and #1782 (rat) or Alu, #1519 and 
#1520 (human)), omission (w/o) of first-round PCR reaction) are given relative to that. (D) Validation of rat integration PCR. 
Parental Rat2 cells were infected with VSV-G pseudotyped HIV-1 GFP vectors carrying either a wildtype integrase (IN wt) or 
catalytically inactive integrase (IN(D64V)). Where indicated, efavirenz (5 μM) was added 1 h before infection. Cultures of 
infected Rat2 cells were monitored for the presence of total HIV-1 cDNA on day 1 (left panel) or day 7 (middle panel) post 
infection. On day 7, cells were also analyzed for the presence of integrated HIV-1 cDNA (right panel).
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Rat2int could be accurately determined by quantifying the
absolute number of HIV-1 cDNA by real-time PCR [22],
thus providing an integration standard. These values were
6.3 and 5 HIV-1 integrants per ng DNA for Rat2int and
HeLaint, respectively.
The PCR strategy for the newly developed integrated pro-
virus in rat cells is depicted in Fig. 4B and described in
detail in the figure legend. This rat integration PCR and a
human integration PCR, the latter essentially following a
published protocol [30], were validated side-by-side using
genomic DNA from Rat2int or HeLaint cells, respectively
(Fig. 4C). The numbers of HIV-1 integrants per ng DNA
were set to 100%. First, omission of LTR primer #1521
from the first-round reaction resulted in a loss of the
amplification signal. Second, a reaction mix without the
cellular primer pair (#1734 and #1782 (rat); #1519 and
#1520 (human)) yielded low signals (9.2% for Rat2int and
1.3% for HeLaint), most likely due to the partial formation
of single-stranded DNA from LTR-containing HIV-1
cDNA by the first-round LTR primer, as previously sug-
gested [30]. Finally, omission of the first-round PCR reac-
tion yielded no signal above background, indicating that
second-round amplification of non-preamplified DNA is
not a disturbing factor (Fig. 4C).
As an additional validation of the rat integration PCR, we
quantified levels of total HIV-1 cDNA and integrated HIV-
1 cDNA in parental Rat2 cells infected with either an inte-
gration-competent or an integration-defective lentiviral
vector, the latter carrying the IN(D64V) catalytic core
mutation [33]. On day 1 after infection, high levels of
total HIV-1 cDNA, which were not detectable after efa-
virenz pre-treatment of cells, were amplified from Rat2
cells challenged with either lentiviral vector (Fig. 4D, left
panel). In cell extracts obtained on day 7 after infection,
levels of total HIV-1 cDNA had decreased to 2.8–8.6% of
the levels on day 1. Most importantly, while integrants
were readily amplified by the newly developed PCR strat-
egy at this late time point in Rat2 cells infected with the IN
wt vector, provirus formation could not be detected in
cells infected with the IN(D64V) vector (Fig. 4D, right
panel). In summary, we have established and validated a
real-time PCR for the quantitative detection of HIV-1 inte-
grants in infected rat cells.
HIV-1 integrates into the genome of rat cells, infected in 
vitro or in vivo, as efficiently as into the genome of human 
cells
To assess the kinetics of formation of different HIV-1
cDNA species and the integration frequency in infected rat
cells, parental Rat2 cells and HeLa cells were simultane-
ously challenged with a VSV-G pseudotyped lentiviral vec-
tor. DNA extracts of cell aliquots taken from infected
cultures at days 1 and 7 after infection were analyzed for
levels of total HIV-1 cDNA and 2-LTR circles [22], as well
as integrants by the assay described above (Fig. 5A). As a
normalisation reference, the level of total HIV-1 cDNA
obtained for each cell line at day 1 after infection was set
to 100%.
Notably, the relative levels of total HIV-1 cDNA and of 2-
LTR circles at days 1 and 7 after infection were similar in
infected Rat2 and HeLa cells. In both species, the latter
episomal DNA species accounted for ~0.01% (day 1) and
~0.001% (day 7) of total HIV-1 cDNA. The 90% reduction
likely reflects the gradual loss of episomes through cell
divisions. At this late time point, the relative levels of inte-
grants in infected Rat2 and HeLa cells were again quite
similar and represented ~0.02% or ~0.005% of the total
HIV-1 cDNA at day 1, respectively. Together, the relative
abundance of these three HIV-1 cDNA species was
remarkably similar in these infected cultures of adherent
cells of rat and human origin. Unfortunately, reliable
detection of HIV-1 integrants in cultured primary T-cells
was precluded by a virus stock production-related con-
tamination with proviral plasmid DNA that was partially
resistant to DNAse treatment (data not shown).
Integration of HIV-1 into the genome occurs efficiently in  infected rat cells Figure 5
Integration of HIV-1 into the genome occurs effi-
ciently in infected rat cells. (A) Parental Rat2 cells and 
HeLa cells were exposed to VSV-G pseudotyped HIV-1 GFP 
vectors and cultivated for 7 days. The relative levels of total 
HIV-1 cDNA, 2-LTR circles, and integrants were quantified 
by specific real time PCR in extracts from cell aliquots taken 
at the indicated time points. All copy numbers per ng DNA 
are depicted relative to the levels of total HIV-1 cDNA on 
day 1 after infection, levels of which were arbitrarily set to 
100%. (B) Three hCD4/hCCR5-transgenic rats and one 
hCCR5-single-transgenic rat were challenged intravenously 
with HIV-1YU-2. On day 4, all animals were sacrificed and 
spleens removed. The levels of all three HIV-1 cDNA species 
were quantified in splenocytes extracts relative to a rat 
GAPDH standard by real-time PCR. Results are presented as 
the arithmetic mean ± S.E.M. of data obtained for the three 
double-transgenic rats.
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In a recent infection study in hCD4/hCCR5-transgenic
rats, we observed that this plasmid contamination of virus
stocks is apparently lost or degraded in vivo, allowing the
exclusive detection of HIV-1 cDNAs synthesized de novo in
splenocyte extracts [22]. Consequently, we challenged
three hCD4/hCCR5-transgenic rats and one hCCR5-sin-
gle-transgenic control rat intravenously with HIV-1YU-2.
Four days after infection, animals were sacrificed, and the
spleens, which harbor high levels of CD4 T-lymphocytes,
were removed. Levels of total HIV-1 cDNA in splenocyte
extracts from infected hCD4/hCCR5-transgenic rats
ranged from 3.2 to 5.3 copies per ng DNA (Fig. 5B). As
important controls of specificity, neither HIV-1 cDNA nor
HIV-1 integrants could be amplified from extracts of the
hCCR5-transgenic animal challenged with the identical
virus inoculum (data not shown). Furthermore, no HIV-1
integrants could be amplified from splenocyte DNA
derived from efavirenz-treated, infected hCD4/hCCR5-
transgenic rats ([22] and data not shown). Collectively,
these results demonstrate that the signals obtained from
samples derived from double-transgenic rats indeed rep-
resent de novo-synthesized HIV-1 cDNA. Here, integrants
were detected at a frequency of 0.03 ± 0.02 copies per ng
DNA, representing 0.65% of the total HIV-1 cDNA at this
time point after infection. Relative levels of 2-LTR circles
were clearly less abundant (0.0023 ± 0.0006 copies per ng
of DNA), representing 0.05% of the total HIV-1 cDNA.
Thus, HIV-1 integrants can be quantitatively detected in
splenocyte extracts from hCD4/hCCR5-transgenic rats fol-
lowing in vivo challenge, and the relative representation of
the three HIV-1 cDNA species analyzed mirrors the results
obtained for in vitro infection studies in cell lines from
both species (Fig. 5A). This suggests that the integration
frequency into the genome of rat T-lymphocytes is not
impaired.
Single-cell analysis reveals that early HIV-1 gene 
expression is diminished in infected primary rat T-cells
Subsequently, we sought to compare levels of early HIV
gene expression in primary T-cells on a single cell level.
Activated T-cell cultures from hCD4/hCCR5-transgenic
rats and human donors were infected with single-round
HIV-1NL4-3E- GFP viruses pseudotyped with YU-2 Env and
analyzed for the expression of the GFP reporter, at the nef
locus, by flow cytometry.
The percentages of GFP-expressing T-cells 3 days after
infection were comparable and efavirenz-sensitive in both
species (Fig. 6A (gate R2)), and only donor-specific varia-
tions were noted (Fig. 6B). Most remarkably, however, the
intensity of GFP expression, reflected by the mean fluores-
cence intensity (MFI) of individual infected cells ana-
lyzed, drastically differed: infected human T-cells
displayed a rather distinct population of GFP high-
expressing cells (Fig. 6A (upper horizontal panel); quanti-
fication in Fig. 6C), whereas T-cells from hCD4/hCCR5-
transgenic rats exhibited only rather low levels of expres-
sion of the early gene product (Fig. 6A, middle horizontal
panel; Fig. 6C). On average, this difference in gene expres-
sion was 5- to 8- fold, irrespective of the viral entry route
(HIV-1YU-2 Env, HIV-1JR-FL Env, VSV-G) (Fig. 6A,C; Fig.
7A). Interestingly, this species-dependent gap was even
more pronounced for an HIV-2ROD-AE- GFP reporter virus,
which showed a 21-fold difference (Fig. 7B). Remarkably,
primary T-cells from native BALB/c mice were largely
refractory to infection by VSV-G pseudotyped HIV-1NL4-3E-
GFP (Fig. 6A, lower horizontal panel, and 6B), and virtu-
ally no GFP-positive cells could be detected despite effi-
cient virion entry (data not shown), consistent with
previous reports [5,14].
We next asked whether this striking difference in gene
expression levels between primary human and rat T-cells
could be due to species-specific differences in the kinetics
of HIV-1 gene expression. Monitoring GFP expression
over the course of 11 days (Fig. 7B), rat T-cells infected
with the replication-deficient HIV-1 reporter virus did not
reveal significant alterations in their levels of early gene
expression. GFP expression levels in human reference cul-
tures peaked at days 6–8 after infection and subsequently
decreased, most likely due to gene silencing or loss of
infected cells from the culture. Thus, a mere delay in viral
gene expression in infected rat T-cells seems unlikely.
Furthermore, this phenotype turned out to be largely spe-
cies-specific: the defect in early HIV-1 gene expression was
seen most drastically in infected T-cell lines from rats,
with a factor of difference ranging from 6- to 100-fold
(Fig. 7C), and also in adherent cell lines, albeit less pro-
nounced (4- to 10-fold factor of difference, Fig. 7D). Inter-
estingly, primary macrophages were an exception,
revealing comparable levels of early HIV-1 gene expres-
sion in both species after infection with the VSV-G pseu-
dotyped HIV-1NL4-3E- GFP reporter virus (Fig. 7E; p = 0.2;
n.s.).
Collectively, these flow cytometric data at single cell level
demonstrate a major post-integrational limitation in viral
gene expression in most rat-derived cells, which may be a
key reason for the failure of primary T-cells from hCD4/
hCCR5-transgenic rats to support HIV-1 replication.
Transient expression of human Cyclin T1 in rat T-cells 
boosts early HIV gene expression
On a molecular level, the inability of mouse Cyclin T1 to
support the Tat-mediated enhancement of HIV transcrip-
tion has been mapped to the C261Y variation in the
mouse protein [34] (parts of the amino acid sequence are
shown in Fig. 8A). Intriguingly, rat Cyclin T1 (genebank:Retrovirology 2007, 4:53 http://www.retrovirology.com/content/4/1/53
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Activated primary rat T-cells exhibit a profound block to HIV-1 replication at the level of early HIV-1 gene expression Figure 6
Activated primary rat T-cells exhibit a profound block to HIV-1 replication at the level of early HIV-1 gene 
expression. (A) Representative FACS dot plots of T-cells from a human donor, a hCD4/hCCR5-transgenic rat, and a BALB/c 
mouse infected with the indicated HIV-1 GFP reporter viruses (50 ng p24 CA per 2–3 × 106 cells) and analyzed for GFP 
expression on day 6 after infection. Viable cells were identified by gating on the live lymphocyte population (gate R1) in the 
FSC/SSC plot (left vertical panels). Gate R2 defines the GFP-positive subpopulation of gate R1. Shown are results obtained 
from cells infected in the absence (middle vertical panels) and presence of efavirenz (EFV) (right vertical panels). (B) Percentage 
of GFP-positive cells obtained for T-cell cultures from four human donors, four hCD4/hCCR5-transgenic rats, and two BALB/
c mice which had been infected as described in A (p = 0.77; n.s.) (C) MFI(GFP) of infected human and rat T-cell cultures shown 
in B (p = 0.02; * = significant).
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Early HIV-1 gene expression is also diminished in infected rat cell lines, but not in infected primary rat macrophages Figure 7
Early HIV-1 gene expression is also diminished in infected rat cell lines, but not in infected primary rat macro-
phages. (A) T-cell cultures were challenged with HIV-1NL4-3E- GFP pseudotyped with either JR-FL Env (n = 2) or VSV-G 
(human (n = 12); rat (n = 24)), or challenged with VSV-G pseudotyped HIV-2ROD-AE- GFP (human (n = 7); rat (n = 12)) and ana-
lyzed for GFP expression at day 3 after infection as described in Fig. 6. Results represent the arithmetic mean ± S.E.M. of the 
indicated number of independent T-cell cultures (p = 0.009; * = significant). (B) Kinetics of GFP expression in primary T-cell 
cultures from human donors or hCD4/hCCR5-transgenic rats infected with single-round YU-2 Env pseudotyped HIV-1NL4-3E- 
GFP. The percentage of GFP-positive cells was quantified every 2–3 days by flow cytometry. Results are the arithmetic mean ± 
S.D. from individual T-cell cultures. (C) Human T-cell lines SupT1, Jurkat, or PM-1, and rat T-cell lines Nb2 or C58, as well as 
(D) human adherent cell lines TZM, 293T, or HeLa, and rat adherent cell lines Rat2, RGE, XC, or HH16, and (E) primary mac-
rophages from both species (human (n = 3); rat (n = 4)) were exposed to VSV-G pseudotyped HIV-1NL4-3E- GFP at a low MOI 
to achieve single cell infections. The MFI of GFP expression was determined on day 3 after infection (p = 0.2; n.s.). Results 
shown in (C-D) represent the arithmetic mean ± S.D. of triplicates. Circles in (E) indicate the arithmetic mean of triplicates 
from one experiment and the horizontal bar shows the arithmetic mean ± S.E.M. of all donors/animals analyzed.
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Ccnt1_predicted XM_235633) shares around 96%
sequence homology with the mouse orthologue, includ-
ing the critical C261Y variation ([4]; Fig. 8A).
To rapidly assess whether expression of human Cyclin T1
can affect HIV gene expression in primary rat T-cells we
performed transient co-transfection studies employing a
recently developed species-adapted non-viral gene deliv-
ery method based on the nucleofection technology [35].
Proviral pHIV-1NL4-3 GFP or pHIV-2ROD-A GFP constructs
were co-transfected with increasing amounts of an expres-
sion vector encoding for either human Cyclin T1 or no
transgene, and cells were analyzed for GFP expression 20
h later by flow cytometry. Remarkably, expression of
human Cyclin T1 enhanced early HIV gene expression in
a concentration-dependent and saturable manner in these
primary rodent T-cells (Fig. 8B). As a control of specificity,
human Cyclin T1 expression did not affect reporter gene
expression from a CMV immediate early promoter-driven
construct, pEGFP-N1, in nucleofected rat T-cells (data not
shown). Moreover, co-transfection of phCyclin T1 and
these proviral constructs into primary T-cells from human
donors did not significantly alter levels of HIV gene
expression (data not shown), indicating that physiologi-
cal levels of Cyclin T1 are not limiting in these cells.
Collectively, these transient ex vivo studies suggest an
underlying transcriptional defect linked to the non-func-
tional rat orthologue and demonstrate a beneficial effect
of Cyclin T1 of human origin on HIV gene expression in
primary rat T-cells.
Discussion
An in-depth assessment of the individual steps in the viral
replication cycle in primary target cells is critical for gen-
erating a highly HIV-1-permissive immunocompetent
rodent model for HIV-1 infection. Here we used quantita-
tive assays to probe consecutive steps in the early phase of
HIV-1 infection. We found that virion fusion, reverse tran-
scription, nuclear import, and HIV-1 integration into the
host genome occur with similar efficiencies in primary T-
cells from hCD4/hCCR5-transgenic rats and humans.
However, one step downstream in the replication cycle,
we find viral gene expression to be greatly diminished in
infected T-cells from rats, ~sixfold for HIV-1NL4-3 and ~20-
fold for HIV-2ROD-A reporter viruses, relative to human ref-
erences, identifying the next relevant replication barrier to
be tackled in this species. Furthermore, we show a benefi-
cial effect of Cyclin T1 of human origin on HIV gene
expression in primary rat T-cells, providing a strong
rationale for the generation of a novel human Cyclin T1-
transgenic rat line.
We began our examination with the entry of the virus into
the cell. Expression of hCD4 and a major human chemok-
ine coreceptor is required for entry into cells of non-
human origin, but the efficiency of virus entry into rodent
cell lines expressing high levels of the HIV-1 receptor/
coreceptor complex was thought to be very low (0.25–
17% of human cells) [9]. To directly compare the efficien-
cies of R5 HIV-1 entry in T-cells from hCD4/hCCR5-trans-
genic rats and human reference cultures, we employed a
sensitive and specific virion-fusion assay [22,24,25]. The
HIV-1 receptor/coreceptor complex at the expressed sur-
face levels is fully functional in rats, implying correct post-
translational modifications, receptor trafficking, and cell-
surface topology of both receptor components. Moreover,
our results provide the first quantitative demonstration of
the success of entry receptor transgenesis towards the
development of an HIV-1-permissive rodent model.
Next we assessed the efficiency and kinetics of HIV-1
cDNA synthesis, nuclear import of the preintegration
complex (2-LTR circle formation), and provirus integra-
tion by real-time PCR. Our post-entry analyses in primary
T-cells and a fibroblast cell line from rats suggest an effi-
cient progression of the viral replication cycle from reverse
Transient expression of human Cyclin T1 in primary rat T- cells boosts early HIV gene expression Figure 8
Transient expression of human Cyclin T1 in primary 
rat T-cells boosts early HIV gene expression. (A) 
Sequence alignment of amino acids 250–290 of human, rat 
and mouse Cyclin T1. * depicts the critical amino acid posi-
tion 261. (B) Proviral pHIV-1NL4-3 GFP or pHIV-2ROD-A GFP 
constructs were co-transfected with increasing amounts of 
an expression vector encoding for either human Cyclin T1 
(phCyclin T1) or no transgene (pcDNA3.1), and cells were 
analyzed for GFP expression 20 h later by flow cytometry.
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transcription over nuclear import to integration. For pri-
mary T-cells, technical limitations did not allow us to con-
duct a direct rat-human species comparison for HIV cDNA
synthesis. However, comparable levels of HIV entry and 2-
LTR circle formation, representing the preceding and sub-
sequent step in the replication cycle, strongly suggest that
reverse transcription occurs efficiently in primary rat T-
cells, although subtle quantitative differences cannot be
excluded.
These observations argue that rat-derived cells are intrinsi-
cally more permissive for these early post-entry steps in
HIV-1 infection than cells from other small animals,
although this difference is not understood at a molecular
level. In this context, two other studies found that defects
in reverse transcription and/or nuclear import in infected
mouse T-cells severely impede viral gene expression and
appear to be recessive in nature [5,14]. Furthermore, aber-
rant intracytoplasmic trafficking of the reverse transcrip-
tion complex in rabbit SIRC cells may be an underlying
reason for a reduced HIV-1 cDNA synthesis in this rodent-
like species [13].
Contrasting the intact HIV-1 entry and early post-entry
steps, we identified a limitation at the level of early HIV-1
gene expression in primary T-cells from double-transgenic
rats that was independent of the viral entry route and that
was apparent in all T-cell lines and adherent cell lines ana-
lyzed. We used flow cytometry to quantify early HIV-1
gene expression through the MFI of GFP as a surrogate for
Nef. This approach allowed a resolution at a single-cell
level in infected cultures rather than bulk analyses using
luciferase or chloramphenicol-acetyl-transferase reporter
systems applied in earlier studies [4,9,11,36]. Our experi-
mental strategy was particularly useful for the cross-spe-
cies comparison since the analysis of gene expression is
much less affected by differences in the efficiency of pre-
ceding steps in the replication cycle. Specifically, earlier
studies assessed HIV-1 gene expression in rodent cell lines
after infection with VSV-G HIV-1 luciferase reporter
viruses [4,7,9], based on the assumption that the effi-
ciency of VSV-G-mediated entry is comparable across spe-
cies. However, in quantitative virion-fusion assays, we
found generally greater VSV-G susceptibility in rat cells
than human references, ranging from 3- to 10-fold for an
identical inoculum in adherent cell lines (Rat2 versus
HeLa), as well as in primary T-cells and macrophages
(data not shown). This previously unrecognized differ-
ence may have led to an overestimation of the capacity of
Rat2 cells to support HIV-1 gene expression [4,7,9]. More-
over, alternative transcriptional assays based on the tran-
sient transfection of LTR reporter and Tat expression
constructs rely on a normalisation of transfection effi-
ciency that involves a third, typically CMV immediate
early promoter-driven reporter, for which species- and cell
type-specific differences in the activity may be an addi-
tional confounding problem.
We reasoned that an impaired activity of the Tat-depend-
ent HIV-1 LTR transactivation [16,17] may underlie the
inefficient early gene expression for HIV-1NL4-3 and HIV-
2ROD-A reporter viruses in primary rat T-cells. In mice, the
inability of Cyclin T1 to support the efficient interaction
with the TAR element when bound to Tat was functionally
mapped to one essential amino acid (C261Y)
[18,34,37,38], and intriguingly, rat Cyclin T1 and the
mouse orthologue both have a tyrosine at this position
[4]. Here, using recently developed technology [35], we
could demonstrate a marked enhancement of HIV gene
expression in primary rat T-cells following transient
expression of human Cyclin T1. This suggests that the
impaired HIV gene expression, at least in part, is due to a
transcriptional defect linked to a non-functional rat Cyc-
lin T1. Furthermore, these ex vivo studies provide a sound
rationale for the generation of human Cyclin T1-trans-
genic rats as an additional genetic modification of the
hCD4/hCCR5-transgenic rat model of HIV infection.
In addition, and despite the fact that the frequency of HIV-
1 integration into the rat genome appeared to be normal,
an underlying defect in the HIV-1 integration site selec-
tion must be considered. The efficiency of viral transcrip-
tion is governed by characteristics of the chromatin
environment at the integration site [39]. Whereas HIV-1
preferentially integrates within active transcription units
[40], MLV favours integration at transcription start regions
[41,42]. The dependence of this process on host factors,
such as lense epithelium-derived growth factor (LEDGF/
p75), that is required for HIV-1, but not for MLV integra-
tion [43,44], makes this a candidate step for species-spe-
cific disturbances of integration site selection.
As an interesting observation, infected macrophages pose
an exception to the otherwise species-specific impairment
at the level of early HIV-1 gene expression in the rat-
human species comparison. This is particularly notewor-
thy since macrophages from hCD4/hCCR5-transgenic rats
are the only rodent cells known to support a productive
and spreading HIV-1 infection, albeit at lower levels than
in human monocyte-derived macrophages [4,11]. Provid-
ing an intriguing explanation, HIV-1, in part, exploits a
distinct set of nuclear transcription factors and alternative
mechanisms of transcriptional regulation in macrophages
than in other cell types, including T-cells (reviewed by
[45-47]). From the perspective of viral evolution, it is
remarkable that macrophages are the only primary cell
type that is permissive for all lentiviruses in their respec-
tive host [48]. Their marked phenotypic difference in the
relative ability to support early gene expression of HIV-
1NL4-3 and HIV-2ROD-A reporter viruses compared to T-cellsRetrovirology 2007, 4:53 http://www.retrovirology.com/content/4/1/53
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may reflect their higher dependence on specific transcrip-
tion factors, including NF-kB and NFAT-1.
Pursuing a conceptually different approach to the genera-
tion of an HIV small animal model, several HIV
xenotransplant models have been developed by introduc-
ing human hematopoietic cells or foetal tissues into
immunodeficient strains of mice. Such animals support
local HIV replication in grafts or, following recent
advancements, also systemic HIV replication with high
level viremia (reviewed by [49]). Unfortunately, adaptive
immune responses in such "humanized" mice were
reported to be low or absent, and these technically chal-
lenging models are not amenable to predictive high-
throughput screenings of drug candidates.
Conclusion
Collectively, the efficiency of all early steps of the HIV-1
replication cycle in CD4 T-cells from hCD4/hCCR5-trans-
genic rats, in clear contrast to mice, up to and including
provirus formation is high. These results are encouraging
for the block-by-block development of a fully permissive
rat model of HIV-1 disease. From a different perspective,
these results provide an important validation of these
HIV-susceptible small animals by underscoring the pre-
dictive value of hCD4/hCCR5-transgenic rats as a model
for the evaluation of antiviral compounds targeting early
events of HIV-1 replication [22]. Furthermore, the dem-
onstration of a marked quantitative limitation at the level
of viral gene expression in rat CD4 T-cells and, impor-
tantly, the beneficial effect of human Cyclin T1 in these
primary cells, provide the basis for the design of strategies
to overcome it.
Methods
Animals
Generation and initial characterization of hCD4/hCCR5-
transgenic rats on an outbred Sprague-Dawley back-
ground have been reported [11]. Female BALB/c mice
were obtained from Charles River Laboratories (Sulzfeld,
Germany). Animals were housed in the central animal
facility of the University of Heidelberg. Animal experi-
ments were conducted according to the German animal
welfare act and with authorization of the Regierungsprä-
sidium Karlsruhe (35-9185.81/G-100/02 and 34395) and
supervised by animal welfare officers of the University of
Heidelberg.
Cells
Cultures of primary T-cells and macrophages from ran-
domly selected human donors and transgenic rats and
BALB/c mice were generated, activated, and cultivated as
reported [11,22,35,50]. Rat cell lines Rat2 (rat fibroblast-
like cell line [ATCC CRL-1764]), RGE (rat glomerular
endothelial cell line [DSMZ ACC 262]), XC (rat sarcoma
cell line [DSMZ ACC 118]), HH16.cl.4 (rat mammary
tumor cell line [DSMZ ACC 358]), C58 (rat T-cell lym-
phoma [ATCC TIB-236]), and Nb2 (rat T-cell lymphoma)
[11] were cultivated as recommended by the original
sources. Human cell lines SupT1, Jurkat, HeLa, PM-1,
TZM-bl and 293T were cultivated as reported [4,50].
Virus stocks
Generation of replication-competent HIV-1YU-2 and HIV-
1R7/3YU-2 Env GFP stocks has been reported [11]. HIV-
1YU-2  virions carrying β-lactamase-Vpr chimeric fusion
proteins (BlaM-Vpr) were produced by triple-transfection
of 293T cells as described [24] with pYU-2 proviral DNA
(60 μg), pBlaM-Vpr (20 μg), and pAdVantage (8 μg) vec-
tors (Promega, Madison, WI) per 15-cm2 dish by calcium
phosphate DNA precipitation. The molecular clone
pNL4-3 E- GFP, carrying an egfp gene within the nef locus
driven by the 5'- LTR, was a kind gift of Dr. Nathaniel
Landau (New York University, New York, NY) [51] via the
NIH AIDS Research and Reference Reagent Program.
Pseudotyping with VSV-G, JR-FL Env and YU-2 Env was
performed as reported [4]. All HIV-1 stocks were charac-
terized for p24 CA concentration by antigen enzyme-
linked immunosorbent assay and/or for infectious titer on
TZM-bl cells [50]. The molecular clone pHIV-2ROD-A was a
gift from Dr. Matthias Dittmar (Department of Virology,
University of Heidelberg, Germany) [52]. Lentiviral vec-
tors were generated by triple-transfection of 293T with
pΔR8.91, pHR.GFP [53] and pVSV-G by calcium phos-
phate DNA precipitation and were DNAse-treated (Turbo
DNAse, Ambion, Dresden, Germany) for 1 h at 37°C (1
unit DNAse/10 μl of concentrated virus stock). MoMLV-
GFP was constructed by introducing the egfp gene driven
from an internal ribosomal entry site (IRES) into the
untranslated region between the env gene and the 3'-LTR
of MoMLV at unique NotI/MluI sites. Titers and replica-
tion kinetics of MoMLV-GFP and MoMLV wildtype were
similar, and GFP expression of the recombinant was sta-
ble over several passages on mouse fibroblasts (data not
shown).
HIV-1 virion-fusion assay
The HIV-1 virion-fusion assay based on flow cytometry
was conducted essentially as described [22,24,25]. Briefly,
primary T-cells were pretreated with the indicated concen-
trations of enfuvirtide (Roche, Indianapolis, IN), TAK-
779, AMD3100 (kind gifts from José Esté) or anti-hCCR5
mAb 2D7 (BD Pharmingen, San Diego, CA) for 15–30
min when indicated. Subsequently, cells were challenged
with HIV-1YU-2 BlaM-Vpr virions (50 ng p24 CA per 2 ×
106 T-cells) for 3–4 h, washed, and then loaded with
CCF2/AM dye overnight. Fusion was monitored with a
three-laser BD FACSAria Cell Sorting System (Becton
Dickinson, San Jose, CA).Retrovirology 2007, 4:53 http://www.retrovirology.com/content/4/1/53
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Quantification of HIV-1 2-LTR circles and total HIV-1 
cDNA
The relative amounts of 2-LTR circles and/or total HIV-1
cDNA in extracts from ex vivo-infected T-cell cultures or in
vivo-infected splenocytes were determined by real-time
PCR with the ABI 7500 sequence detection system
(Applied Biosystems, Foster City, CA) essentially as
described [22]. Results for HIV-1 cDNA species were nor-
malized to the amount of cellular DNA, which was quan-
tified in a parallel amplification of rat GAPDH gene DNA
or human RNaseP gene DNA (Applied Biosystems).
Genomic standards were derived from dilutions of
genomic DNA extracted from uninfected primary rat or
human T-cell cultures and uninfected Rat2 or HeLa cells.
The lowest limit of detection was 0.001 2-LTR circle copies
per ng DNA and 0.02 total HIV-1 cDNA copies per ng
DNA. All samples were run in duplicate or triplicate. Data
analysis was performed using the 7500 System Software
(Applied Biosystems).
Quantification of integrated HIV-1 DNA
The procedure used to establish the quantitative nested
PCR strategy for HIV-1 integrants in the rat genome and
the generation of cell lines that served as integration
standards, Rat2int and HeLaint, is described in the Results
section and in Fig. 4. Briefly, in a first PCR reaction, HIV-
1 integrants were amplified by one primer annealing to
the LTR (primer #1521 [30]), which contains a lambda-
phage heel sequence at the 5' end, and by two outward-
facing primers that target the highly redundant identifier
(ID) consensus sequence within the rat BC1 RNA gene
(primers #1734, 5'-GGTAACTGGCACACACAACC-3' and
#1782, 5'-CTGAGCTAAATCCCCAACCC-3'). The condi-
tions for the first PCR were (a) 3 min at 94°C, (b) 12
cycles of 30 sec at 94°C, 30 sec at 57°C, 4 min at 72°C,
and (c) 10 min at 72°C. The second PCR amplified the
first-round amplicon with a lambda-specific primer
(primer #1522 [30]) and an LTR primer (#1523, 5'-
TGACTAAAAGGGTCTGAGGGATCT-3') and an LTR-spe-
cific probe (probe #1524, 5'-(FAM)-TTACCAGAGT-
CACACAACAGACGGGCA-(rhodamine (TAMRA)-3').
The second-round cycling conditions were identical to
those used to determine the total amounts of HIV-1 cDNA
and 2-LTR circles [22]. For the PCR to detect HIV-1 inte-
grants in human cells, the conditions and reagents were
identical, except that a primer pair targeting the Alu ele-
ments served as cellular anchor primers (forward primer
#1719 [30] and reverse primer #1720 [54]). For each inte-
gration PCR, a control reaction in which the cellular
primer pair was omitted was run in parallel. This value
was routinely subtracted from the total signal. For stand-
ard curves, dilutions of genomic DNA from Rat2int and
HeLaint covering 3.9 logs were used. The lowest detection
standard of the PCR was 0.07 and 0.05 HIV-1 integrants
per ng DNA, for integrated provirus in rat and human
genomic DNA, respectively.
In vivo-infections in transgenic rats
Three hCD4/hCCR5-transgenic rats (age: 11 weeks;
weights: 196–222 g) were anesthetized and challenged by
tail vein injection via a plastic catheter with HIV-1YU-2
(corresponding to 3000 ng p24 CA per rat), essentially as
described [11,22]. One hCD4-single-transgenic rat, inoc-
ulated with the identical virus dose, served as negative
control. On day 4 post-challenge, all animals were sacri-
ficed with CO2 and bilateral thoracotomy, and spleens
were removed. Total DNA was prepared from single-cell
suspensions of splenocytes with DNeasy tissue kits (Qia-
gen, Hilden, Germany) and analyzed by real-time PCR.
HIV-1 single-round infections
Activated primary T-cells and T-cell lines (3 × 106), adher-
ent cell lines (0.8–1 × 105), or primary macrophages (~2
× 105 cells) from rats and humans were pretreated with
efavirenz (10 μM, 1 h, Bristol-Myers Squibb, Uxbridge,
UK) where indicated and subsequently challenged with
single-round HIV-1NL4-3E- GFP reporter viruses pseudo-
typed with the indicated Envs (corresponding to 50–200
ng HIV-1 p24 CA). On day 3 after infection, the percent-
age of GFP-positive cells and the GFP mean fluorescence
intensity (MFI(GFP)) were determined on a FACSCalibur
using BD CellQuest Pro 4.0.2 Software (BD Pharmingen).
Nucleofection of primary rat T cells
Activated primary rat T cells were transfected by nucleofec-
tion as described [35]. For the analysis of the effect of tran-
siently expressed human Cyclin T1, the expression vector
phCyclin T1 [15] was utilized. Flow cytometric analysis of
viable, GFP-positive cells was performed 20 hours post
nucleofection as reported.
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